Apr 01 2025
The ALBA Study for idiopathic hypersomnia (IH) is now enrolling

Posted at Apr 01 2025
h in Clinical Trial by Cara Weaver

The investigational drug, TAK-360, is an oral, highly selective orexin 2 receptor (OX2R) agonist. With its potential to improve excessive daytime sleepiness (EDS) and related symptoms through a novel mechanism of action, TAK-360 could offer, if proven effective, a new treatment option for people with IH.

Visit sleepdisorderstudies.com/WUN to learn more about the ALBA Study.

Print page

Apr 01 2025 The ALBA Study for idiopathic hypersomnia (IH) is now enrolling

0 events, 30

0 events, 30

2 events, 31

2 events, 31

1 event, 1

1 event, 1

2 events, 2

2 events, 2

1 event, 3

1 event, 3

1 event, 4

1 event, 4

2 events, 5

2 events, 5

0 events, 6

0 events, 6

2 events, 7

2 events, 7

1 event, 8

1 event, 8

2 events, 9

2 events, 9

1 event, 10

1 event, 10

1 event, 11

1 event, 11

1 event, 12

1 event, 12

0 events, 13

0 events, 13

2 events, 14

2 events, 14

1 event, 15

1 event, 15

2 events, 16

2 events, 16

2 events, 17

2 events, 17

1 event, 18

1 event, 18

1 event, 19

1 event, 19

0 events, 20

0 events, 20

2 events, 21

2 events, 21

1 event, 22

1 event, 22

2 events, 23

2 events, 23

1 event, 24

1 event, 24

1 event, 25

1 event, 25

2 events, 26

2 events, 26

Wake Up Narcolepsy 2025 National Summit

Wake Up Narcolepsy 2025 National Summit

0 events, 27

0 events, 27

2 events, 28

2 events, 28

Apr 01 2025
The ALBA Study for idiopathic hypersomnia (IH) is now enrolling